Expired activity
Please go to the PowerPak homepage and select a course.

Basic Concepts and Evolution of Biosimilars in Patient Therapy:
Implications for Pharmacy Management

This activity is provided by the Potomac Center for Medical Education and Rockpointe and is supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.


Gary I. Cohen, MD, FACP, FASCO
Director Emeritus
Sandra and Malcolm Berman Cancer Institute
Greater Baltimore Medical Center
Associate Professor
Johns Hopkins Oncology
Baltimore, MD

Alex Ganetsky, PharmD, BCOP
Clinical Pharmacy Specialist
Hospital of the University of Pennsylvania
Philadelphia, PA


Faculty Speaker/Steering Committee
The faculty/steering committee reported the following relevant financial relationships that they or their spouse/partner have with commercial interests:

Gary I. Cohen, MD, FACP, FASCO: Stock/Shareholder: AbbVie, Celgene

Alex Ganetsky, PharmD, BCOP: Advisory Board: Jazz; Speaker's Bureau: Amgen, Incyte

Non-faculty Content Contributors
Non-faculty content contributors and/or reviewers reported the following relevant financial relationships that they or their spouse/partner have with commercial interests:

Shawna Graves, PhD; Blair St. Amand; Lindsay Scott, PT, DPT, ATC: Nothing to disclose


acpeThe Potomac Center for Medical Education is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

For information about the accreditation of this program, please email: contact@potomacme.org.


The Potomac Center for Medical Education designates this educational activity for a maximum of 1.00 hours (0.10 CEUs) of continuing education credit.

UAN: 0418-9999-18-001-H04-P

Credits: 1.00 hours (0.10 ceu)
Published: January 31, 2018
Expires: January 31, 2019
Type of Activity: Knowledge
Media: Internet

Fee Information: There is no fee for this educational activity.

Estimated time to complete activity: 60 minutes


The intended audience for this educational initiative includes hospital-based pharmacists and other community-based medical clinicians involved in the potential care of patients with biosimilars.


During the period January 31, 2018 through January 31, 2019, participants must 1) read the learning objectives and faculty disclosures; 2) review the full content of the educational activity; and 3) complete the posttest and the evaluation form. To answer the questions, click on your selected choice for each answer then proceed to the next question. Once completed, click on Submit Posttest at the bottom of the page. Your posttest will automatically be graded. If you successfully complete the posttest (score of 66% or higher), your statement of participation will be made available immediately. Click on the View Statement of Participation link and print the statement for your records. If you receive a score lower than 66%, you will receive a message notifying you that you did not pass the posttest. You will have 5 opportunities to pass the posttest. To receive Credit, you must provide your date of birth (mm/dd) and NABP number. All Credit information will be uploaded into CPE monitor within 30 days.


The introduction of biosimilars has changed the therapeutic landscape for managing chronic conditions in the European Union and other international regions. The regulatory requirements for biosimilars are rapidly changing, creating confusion among clinicians related to their safe use in treatment in place of biologic originators and their interchangeability, as well as bringing up questions regarding extrapolation of indications.

"Basic Concepts and Evolution of Biosimilars in Patient Therapy: Implications for Pharmacy Management" will guide clinical pharmacists in the integration of biosimilars into evidence-based treatment choices that are efficacious and safe. Guidance is also provided for the navigation of the changing treatment landscape surrounding biosimilars and the current and future roles for biosimilars in therapy.


This program is designed to address the following IOM competencies: provide patient-centered care and employ evidence-based practice.

At the conclusion of this activity, participants should be able to demonstrate the ability to:

  • Assess the pharmacodynamics, risks, benefits, and challenges of expanding the treatment landscape with biosimilar agents in comparison to their originator drugs
  • Delineate the role of health-system pharmacists in incorporating biosimilars into pharmaceutical formularies and prescribing for therapy
  • Summarize possible administrative and cost barriers to biosimilar implementation, including impediments to formulary adoption


Please ensure the computer system you plan to use meets the following minimum requirements:

  • Operating System: Windows 98 or higher & Macintosh 2.2 or higher
  • Internet Browser (Mac &/Windows): Internet Explorer 6.0 or higher, Google Chrome, Safari 5.0.6 or higher, Firefox 3.0.3 or higher & Opera 5 or higher
  • Broadband Internet connection: Cable, High-speed DSL & any other medium that is internet accessible
  • Peripherals: Computer speakers or headphones
  • Monitor Screen Resolution: 320 x 480 or higher
  • Media Viewing Requirements: Adobe Reader, Microsoft PowerPoint, Flash Player & HTML5

Disclosure/Conflict of Interest Statement

Potomac Center for Medical Education (PCME) adheres to the policies and guidelines set forth to providers by the Accreditation Council for Pharmacy Education (ACPE), the Accreditation Council for Continuing Medical Education (ACCME), and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous.

All persons in a position to control the content of a continuing medical education program provided by PCME are required to disclose any relevant financial relationships with any commercial interest to PCME as well as to learners. All conflicts of interest are identified and resolved by PCME in accordance with the Standards for Commercial Support in advance of delivery of the activity to learners.

The content of this activity was vetted by an external reviewer to assure objectivity and that the activity is free of commercial bias.

FDA Disclosure

The contents of some CE activities may contain discussions of non-approved or off-label uses of some agents mentioned. Please consult the prescribing information for full disclosure of approved uses.

Privacy Policy

Click here for the privacy policy.